Research Article
Salivary Antioxidant Profile in Patients with Systemic Sclerosis and Periodontitis
Table 1
Disease characteristics of individuals with systemic sclerosis.
| | Demographics | SSc group () |
| | Clinical form (diffuse: limited) | 16 : 4 | | Disease duration () | 5.22 (±0.62) | | Disease severity and activity () | | | Modified Rodnan’s skin score | 7.39 (±4.1) | | Disease activity score | 2.56 (±1.33) | | Systemic involvement (no. of patients, %) | | | Arthritis | 5 (20) | | Pulmonary fibrosis | 7 (35) | | Renal crisis | 4 (20) | | Esophageal involvement | 4 (20) | | Heart involvement | 5 (25) | | Autoantibodies (%) | 20 (100) | | Antinuclear (ANA) | 7 (35) | | Antitopoisomerase I (anti-SCL-70) | 16 (80) | | Anticentromere (ACA) | 7 (35) | | Treatment (no. of patients, %) | | | Corticosteroids | 8 (40) | | Immunosuppressive drugs | 12 (60) | | Calcium channel blockers | 9 (45) | | ACE inhibitors | 8 (40) | | Antimalarics | 1 (5) |
|
|
